Graf R, Guscetti F, Welle M, Meier D, Pospischil A
Collegium Helveticum, Universität Zürich und Eidgenössische Technische Hochschule Zürich, Switzerland.
Institut für Veterinärpathologie Vetsuisse Fakultät Universität Zürich, Zurich, Switzerland.
J Comp Pathol. 2018 Aug;163:1-5. doi: 10.1016/j.jcpa.2018.06.008. Epub 2018 Jul 18.
Feline injection site sarcomas (FISS) were first described in the early 1990s. Despite extensive research, the pathogenesis of these tumours has not been elucidated conclusively. Their appearance and the marked increase in their incidence has been mainly connected to the injection of vaccines, and it is assumed that a chronic inflammatory reaction at the injection site triggers subsequent malignant transformation. The role of alum-based adjuvants has been discussed, but is controversial. The present study of the Swiss Feline Cancer Registry (SFCR) with data from 2009 to 2014 revealed a marked decrease of the incidence of fibrosarcomas compared with the previous observation period. Notably, this drop occurred after a non-adjuvanted feline leukaemia virus vaccine was introduced in Switzerland in 2007. This observation, together with the previous findings of the SFCR, further supports the notion that alum-adjuvanted vaccines are involved in the genesis of FISS and that non-adjuvanted vaccines might be safer for cats.
猫注射部位肉瘤（FISS）最早于20世纪90年代初被描述。尽管进行了广泛研究，但这些肿瘤的发病机制尚未得到最终阐明。它们的出现及其发病率的显著增加主要与疫苗注射有关，据推测，注射部位的慢性炎症反应会引发随后的恶性转化。基于明矾的佐剂的作用一直存在争议。瑞士猫科动物癌症登记处（SFCR）对2009年至2014年数据的当前研究显示，与之前的观察期相比，纤维肉瘤的发病率显著下降。值得注意的是，这一下降发生在2007年瑞士引入非佐剂猫白血病病毒疫苗之后。这一观察结果，连同SFCR之前的研究结果，进一步支持了明矾佐剂疫苗与FISS的发生有关，且非佐剂疫苗可能对猫更安全这一观点。
